IgA Nephropathy (IgAN) market across the 7MM is estimated at approximately USD 878 million in 2025, analyses DelveInsight

Leading companies such as Vertex Pharmaceuticals, Vera Therapeutics, Novartis, and AstraZeneca (Alexion Pharmaceuticals) are actively advancing new treatment options.
The IgA Nephropathy (IgAN) market across the seven major markets (7MM) is estimated at approximately USD 878 million in 2025, rising from nearly USD 730 million in 2024. The market is projected to expand at a strong CAGR of 30.5% between 2025 and 2034, reaching nearly USD 9.7 billion by 2034, with the United States representing the largest share.

In 2024, around 415,000 diagnosed prevalent cases of IgAN were reported across the 7MM. Market growth will be driven by increasing disease awareness, improved diagnostic techniques, greater use of kidney biopsies, and the introduction of innovative therapies such as povetacicept, atacicept, zigakibart, and ULTOMIRIS.

Currently approved treatments remain limited, including VANRAFIA (atrasentan) and FABHALTA (iptacopan) from Novartis, FILSPARI (sparsentan) from Travere Therapeutics, and TARPEYO/KINPEYGO (budesonide) from Asahi Kasei/Calliditas Therapeutics. However, safety concerns continue to challenge long-term treatment adoption, as corticosteroids may lead to hypertension and infections, while complement inhibitors increase infection risk. These limitations highlight the growing need for safer, targeted therapies suitable for chronic disease management, especially in pediatric and elderly populations.

Notably, in April 2025, Novartis received FDA accelerated approval for Vanrafia Registered (atrasentan) to reduce proteinuria in adults with primary IgAN at risk of rapid progression. In the same month, Vera Therapeutics completed enrollment in the pivotal Phase III ORIGIN trial evaluating atacicept in IgAN patients.

Overall, the IgA Nephropathy market is poised for significant expansion through 2034, supported by robust pipeline advancements and rising diagnosed patient populations.

DelveInsight's report, "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast - 2034," offers a comprehensive analysis of IgA Nephropathy, covering historical and projected epidemiological data along with detailed market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The study provides an overview of existing treatment approaches, upcoming therapies, individual drug market shares, and the present as well as anticipated IgA Nephropathy market size from 2020 to 2034 across the seven major markets. Additionally, the report evaluates treatment algorithms, growth drivers, barriers, and unmet clinical needs to identify strategic opportunities and assess the market's long-term potential.

Request for a Free Sample Report @ IgA Nephropathy Market Forecast [https://www.delveinsight.com/report-store/iga-nephropathy-igan-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Highlights from the IgA Nephropathy Market Report

* The combined IgA Nephropathy market size across the 7MM and China was nearly USD 500 million in 2022 and is expected to expand steadily during 2023-2034.
* In 2022, the United States accounted for the largest market share among the 7MM, generating approximately USD 160 million, with projections indicating further growth through 2034.
* Prominent companies engaged in IgA Nephropathy drug development include Calliditas Therapeutics AB, Travere Therapeutics, Inc., Omeros Corporation, Novartis, RemeGen, Chinook Therapeutics, Inc., Vera Therapeutics, Inc., Otsuka Pharmaceutical, and others.
* The disease shows higher incidence in males compared to females.
* Prevalence rates vary geographically, ranging from 10-20% of primary glomerulonephritis cases in the United States, 20-30% in parts of Europe, and up to 40-50% in developed Asian countries.
* A global systematic review of biopsy-based studies estimates a minimum incidence of 2.5 cases per 100,000 individuals annually. Most data originated from Europe and North America, with limited representation from Japan.
* While IgA Nephropathy may follow a relatively mild course in many individuals, a significant proportion of patients experience gradual progression to end-stage renal disease (ESRD). Approximately 15% may develop ESRD within 10 years and about 20% within 20 years, depending on disease classification criteria.

Recent Developments in the IgA Nephropathy Market

* In Febriuary 2026, Novartis announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia Registered (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p = 0.057) at Week 136, 4 weeks after the end of study treatment.
* In January 2026, Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced the atacicept Biologics License Application (BLA) for the treatment of adults with immunoglobulin A nephropathy (IgAN) was accepted for Priority Review by the U.S. Food and Drug Administration (FDA). The BLA, which was submitted using the Accelerated Approval Program, was assigned a Prescription Drug User Fee Act (PDUFA) target action date of July 7, 2026. If approved, atacicept could offer patients an autoinjector for at-home self-administration of a once-weekly subcutaneous injection.
* In November 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce the U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. VOYXACT is a self-administered, subcutaneous injection dosed every four weeks. VOYXACT was granted accelerated approval based on the VISIONARY Phase 3 interim analysis, where it achieved a significant placebo-adjusted treatment effect of 51% (P



This release was published on openPR.